| |
Summary of each treatment
|
FMS/RSV vs FMS
|
FMS/RSV vs RSV
|
|---|
| |
FMS/RSV
|
FMS
|
RSV
|
Difference(SE)
|
P-valued
|
Difference(SE)
|
P-valued
|
|---|
| |
N = 35
|
N = 36)
|
N = 37
|
(95% C.I.)
| |
(95% C.I.)
| |
|---|
|
siSBP
| | | | | | | |
|
Response ratea, n (%)
|
26 (74.29)
|
23 (63.89)
|
15 (40.54)
|
10.40 (10.89)
| |
33.75 (10.94)
| |
|
95% CI
|
(59.81, 88.77)
|
(48.20, 79.58)
|
(24.72, 56.36)
|
(−10.95, 31.75)
|
0.390
|
(12.30, 55.19)
|
0.010
|
|
Control rateb, n (%)
|
26 (74.29)
|
23 (63.89)
|
13 (35.14)
|
10.40 (10.89)
| |
39.15 (10.78)
| |
|
95% CI
|
(59.81, 88.77)
|
(48.20, 79.58)
|
(19.75, 50.52)
|
(−10.95, 31.75)
|
0.358
|
(18.03, 60.28)
|
0.003
|
|
LDL-C
| | | | | | | |
|
Goal attainment ratec, n (%)
|
33 (94.29)
|
7 (19.44)
|
34 (91.89)
|
74.84 (7.67)
| |
2.39 (5.96)
| |
|
95% CI
|
(86.60, 100.00)
|
(6.52, 32.37)
|
(83.10, 100.00)
|
(59.80, 89.88)
|
<0.001
|
(−21.13, 25.12)
|
0.082
|
-
FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, siSBP sitting systolic blood pressure, LDL-C low-density lipoprotein cholesterol, CI confidence interval, SE standard error
-
aResponse Rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg or Chang from Baseline of siSBP at Week 8 ≥ 20 mmHg
-
bControl rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg
-
cGoal attainment rate of LDL-C: proportion of the subjects whose LDL-C < 100 mg/dL (high risk), LDL-C < 130 mg/dL (moderate high or moderate risk), LDL-C < 160 mg/dL (low risk)
-
dComparison between combination therapy and monotherapy was analyzed by Logistic regression model adjusted for baseline values, age, and gender, smoking status
